Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

Montefiore Medicine Academic Health System

Status and phase

Completed

Phase 2

Conditions

Prostatic Neoplasms

Treatments

Drug: Abiraterone Acetate

Drug: Prednisone

Study type

Interventional

Funder types

Other

Identifiers

NCT03565835

2017-8506

Details and patient eligibility

About

The goal of this study is to find out if patients with prostate cancer being treated with the medications abiraterone and prednisone can discontinue hormone injections (examples include leuprolide, goserelin, triptorelin and degarelix). Abiraterone and prednisone are pills used to treat patients with prostate cancer. When abiraterone and prednisone are used, hormone injections are usually continued to maintain a low testosterone level in the blood. This study is being done to find out if testosterone in the blood will stay low while abiraterone and prednisone are used without continued hormone injections.

Full description

Abiraterone inhibits the CYP17A enzyme, which is a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in metastatic castration-resistant prostate cancer (mCRPC) in both chemotherapy-naïve and in the post-docetaxel setting based upon results from two randomized phase III studies. Abiraterone is also proven to extend survival in the metastatic, hormone-naïve population based on two phase III studies. Abiraterone is a castrating agent, but, other than a small first in human study, all clinical studies have been done in conjunction with gonadotropin-releasing hormone (GnRH) analogues. Maintaining castrate level of serum testosterone is critical in the treatment of metastatic prostate cancer. It is unknown if GnRH analogues must be continued to maintain castrate levels of serum testosterone in patients treated with abiraterone.

Enrollment

31 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient must be able to provide study-specific informed consent prior to study entry
Age ≥ 18
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Pathologically proven diagnosis of prostate adenocarcinoma
Patients must have metastatic prostate cancer
Patients may have mCRPC or may have metastatic castration-sensitive disease.
Patients must be maintained on a GnRH analogue (agonist (leuprolide, goserelin, triptorelin, histrelin, deslorelin) or antagonist (degarelix))
The patient and the investigator have decided that the next line of cancer therapy will be abiraterone plus prednisone and the initial dose of abiraterone will be 1000 mg daily. Or patients may already be on abiraterone with prednisone at a dose of 1000 mg daily along with a GnRH analogue.
Lab values meeting the following criteria
Total testosterone level of <50 ng/dl
Total bilirubin < 2.0 X Upper Limit of Normal (ULN)
Aspartate aminotransferase (AST) ≤ 3 X ULN
Alanine aminotransferase (ALT) ≤ 3 X ULN
Absolute Neutrophil Count > 1.5 K/mm3
Platelets > 100 K/mm3
Hemoglobin ≥ 9.0 g/dL
Calculated creatinine clearance ≥ 30 mL/min

Exclusion criteria

History of bilateral orchiectomy
History of hypopituitarism
For patients not yet started on abiraterone with prednisone, uncontrolled hypertension (systolic blood pressure >170 mm Hg or diastolic blood pressure >100 mm Hg)
Patients must not have New York Heart Association Class III or IV heart failure at the time of screening. Patients must not have any unstable angina, myocardial infarction, or serious uncontrolled cardiac arrhythmia within 6 months prior to registration
Any other serious illness or medical condition that the principal investigator feels would make the patient a poor candidate for this study